Effect of Sildenafil on Pulmonary Circulation and Cardiovascular Function in Near-Term Fetal Sheep During Hypoxemia by Bhide, Amarnath et al.
Original Article
Effect of Sildenafil on Pulmonary Circulation
and Cardiovascular Function in Near-Term
Fetal Sheep During Hypoxemia
Amarnath Bhide, PhD1, Leena Alanne, MD2, Juha Rasanen, PhD3,4,
Heikki Huhta, PhD4, Juulia Junno, MD4, Merja Kokki, PhD5,
Tiina Erkinaro, PhD6, Pasi Ohtonen, MSc7,
Mervi Haapsamo, PhD8, and Ganesh Acharya, PhD1,9
Abstract
Sildenafil is a potential new treatment for placental insufficiency in human pregnancies as it reduces the breakdown of vasodilator
nitric oxide. Pulmonary vasodilatation is observed in normoxemic fetuses following sildenafil administration. Placental insufficiency
often leads to fetal hypoxemia that can cause pulmonary vasoconstriction and fetal cardiac dysfunction as evidenced by reduced
isovolumic myocardial velocities. We tested the hypotheses that sildenafil, when given directly to the hypoxemic fetus, reverses
reactive pulmonary vasoconstriction, increases left ventricular cardiac output by increasing pulmonary venous return, and
ameliorates hypoxemic myocardial dysfunction. We used an instrumented sheep model. Fetuses were made hypoxemic over a
mean (standard deviation) duration of 41.3 (9.5) minutes and then given intravenous sildenafil or saline infusion. Volume blood
flow through ductus arteriosus was measured with an ultrasonic transit-time flow probe. Fetal left and right ventricular outputs
and lung volume blood flow were calculated, and ventricular function was examined using echocardiography. Lung volume blood
flow decreased and the ductus arteriosus volume blood flow increased with hypoxemia. There was a significant reduction in left
ventricular and combined cardiac outputs during hypoxemia in both groups. Hypoxemia led to a reduction in myocardial iso-
volumic velocities, increased ductus venosus pulsatility, and reduced left ventricular myocardial deformation. Direct adminis-
tration of sildenafil to hypoxemic fetus did not reverse the redistribution of cardiac output. Furthermore, fetal cardiac systolic and
diastolic dysfunction was observed during hypoxemia, which was not improved by fetal sildenafil treatment. In conclusion,
sildenafil did not improve pulmonary blood flow or cardiac function in hypoxemic sheep fetuses.
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Introduction
The fetal pulmonary vasculature becomes responsive to oxygen
with advancing gestational age.1 The pulmonary circulation
responds to a decrease in partial pressure of O2 (pO2) by
vasoconstriction and reduced lung volume blood flow.2,3 There
is also peripheral vasoconstriction and centralization of the
blood flow.4,5 Fetal hypoxemia is often found in placental
insufficiency.6 Hypoxemia, particularly when associated with
acidemia, affects fetal cardiac function.7-9
In normal pregnancy, the vasodilator nitric oxide contri-
butes to the vasodilation and reduced vascular resistance seen
in the uteroplacental circulation.10,11 The nitric oxide second
messenger cyclic guanosine monophosphate is enzymatically
degraded by phosphodiesterases.12 Sildenafil citrate (sildena-
fil), an inhibitor of phosphodiesterase-5, is able to enhance the
vasodilatory action of nitric oxide.12 It has been reported to
increase placental blood flow and reduce the severity of fetal
growth restriction.13 The pulmonary circulation is responsive
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to sildenafil in normoxemic foetuses.14 Sildenafil infusion to
the fetus led to 60% reduction in pulmonary vascular resistance
in normoxemic fetuses in the sheep model.14 The effect of
sildenafil on pulmonary circulation in the presence of hypox-
emia or its effect on hypoxemia-induced cardiac dysfunction is
not known.
We reasoned that hypoxemia-induced pulmonary vasocon-
striction will lead to a reduction in volume blood flow to the
lungs and consequently pulmonary venous return to the left
atrium. This could potentially be compensated by increased
shunting across the foramen ovale. However, fetal ability to
increase foramen ovale shunting is limited.15 Therefore, left
ventricular (LV) output could be maintained only if pulmonary
volume blood flow could be increased by reversing
hypoxemia-induced pulmonary vasoconstriction using sildena-
fil. Furthermore, experimental studies in the chick embryo have
shown that sildenafil prevents the increase in phosphodiester-
ase expression, protects against oxidative stress, and nor-
malizes nitric oxide bioavailability in the fetal heart in
chronic hypoxemic environment.16
We hypothesized that administration of sildenafil to the
hypoxemic fetus reverses pulmonary vasoconstriction, main-
tains LV cardiac output, and ameliorates myocardial dysfunc-
tion. The first aim of our study was to examine whether
sildenafil, when given directly to the fetus, can at least partially
relieve reactive pulmonary vasoconstriction in a hypoxemic
fetus. This could potentially increase lung volume blood flow
and LV output that is crucial to maintain adequate cerebral
volume blood flow and perfusion pressure. Second aim was
to assess the effects of sildenafil on right ventricular (RV) and
LV function in hypoxemic fetus.
Methods
The study protocol was reviewed and approved by the National
Animal Experiment Board of Finland (ESAVI/1007/04.10.07/
2014). The animal care and experimental procedures were con-
ducted according to the national legislation and the EU Direc-
tive 2010/63/EU.17 A total of 24 pregnant sheep underwent
surgery for fetal instrumentation at 128 (standard deviation
[SD] ¼ 2.9) days’ gestation. The details of the surgical proce-
dure have been previously described.8 In brief, pregnant sheep
were operated under general anesthesia. Induction of anesthe-
sia was achieved with intravenous propofol (4-7 mg/kg) and
maintenance with isoflurane (1.5%-2.5%) in an oxygen–air
mixture delivered via an endotracheal tube. Intravenous
boluses of fentanyl (0.05-0.15 mg) were administered as
required. A midline laparotomy was performed, and the fetal
head and neck were delivered through a small hysterotomy
incision. Catheters were introduced into the internal jugular
vein and the carotid artery to access venous and arterial circu-
lations and to collect blood samples. A small left lateral
thoracotomy was performed at the level of third intercostal
space, and the ductus arteriosus was identified and dissected.
A 4.0-mm ultrasonic transit-time flow probe was secured
around the vessel for the measurement of ductus arteriosus
volume blood flow. The thoracotomy was closed. Electrocar-
diogram leads were placed under the skin and securely attached
on the fetal chest using sutures. A separate catheter was placed
in the amniotic cavity to measure intra-amniotic pressure. After
the replacement of amniotic fluid by 0.9% warm saline and
closure of the surgical wounds, all catheters and cables were
tunneled subcutaneously and exteriorized through a small skin
incision in the ewe’s flank.
After a 5-day recovery period, experiments were performed
under general anesthesia as described above. The mean (SD)
gestational age was 132 (3.3) days. Fetal systemic venous and
carotid artery blood pressure and arterial blood gas values were
monitored. Two-dimensional echocardiography was performed
using a Vivid 7 ultrasound system (GE Medical Systems, Hor-
ten, Norway) with a 10-MHz phased-array transducer. Cine
loops of high-resolution cardiac images of the longitudinal and
cross-sectional views of the RV and LV were recorded at a high
frame rate (more than 150 frames/s) and LV and RV global
longitudinal strains were measured off-line by speckle tracking
using acoustic-tracking software (EchoPAC; GE Medical Sys-
tems). The ductus arteriosus volume blood flow (QDA) was
directly measured by ultrasonic transit-time flow probe. Fetal
right ventricular cardiac output (RVCO) and left ventricular
cardiac output (LVCO) were calculated using 2-dimensional
ultrasound and pulsed-wave Doppler techniques to measure
aortic and pulmonary valve diameters and blood flow velocity
waveforms as described.1 Lung volume blood flow (QP) was
calculated by subtracting QDA from RVCO. Right pulmonary
artery pulsatility index (RPA PI) was calculated from its Dop-
pler blood flow velocity waveform.1 Tissue Doppler technique
was used to record LV and RV lateral wall movement at the
atrioventricular valve level during the cardiac cycle.18 Isovo-
lumic contraction velocity (IVCV) and isovolumic relaxation
velocity (IVRV) of the RV- and LV-free wall were measured.18
The PI of the ductus venosus (DV) was calculated from its
blood flow velocity waveform. The analyses of the ultrasound
recordings were performed by examiners blinded to the alloca-
tion of intervention. Systemic volume blood flow was calcu-
lated by subtracting QP from combined cardiac output.
Systemic vascular resistance was calculated by dividing the
mean arterial pressure (MAP, mm Hg) by systemic volume
blood flow (mL/min), indexed to fetal weight (kg), and
expressed as mm Hgmin/mL/kg.19
Fetal cardiac systolic function was assessed by tissue
Doppler-derived IVCV and myocardial strain using speckle
tracking. Diastolic function was evaluated using tissue
Doppler-derived IVRV and DV PIV. The ultrasound examina-
tion was repeated during each phase of the experiment to col-
lect data. The still images and video clips of the ultrasound
examination were stored digitally. Using off-line analysis, an
observer (LA or AB) blinded to group allocation calculated
volume flows as well as other echocardiographic measure-
ments, such as myocardial isovolumic velocities and strain.
After baseline data collection, maternal hypoxemia was
induced by connecting the ewe to a rebreathing circuit, thereby
reducing the maternal fraction of inspired O2 (FiO2) to reach
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the oxygen saturation level of 80% over a mean (SD) duration
of 41.3 (9.5) minutes. This was verified by maternal arterial
blood gas analyses. The blood gas values (corrected for 39oC)
were analyzed just before ultrasonographic data collection at
each study point (Abbott – iSTAT 1, East Windsor, New Jer-
sey). The hypoxemia phase data were collected 30 minutes
after desired maternal oxygen saturation level was reached.
Thereafter, 12 fetuses were allocated to receive sildenafil infu-
sion into the internal jugular vein (sildenafil citrate 0.8 mg/mL)
that was diluted 1:1 in saline and infused at a rate of 2.5 mL/h
(1.0 mg/h) and 12 fetuses receiving saline infusion were used as
controls, respectively. Data were collected at 30 and 120 min-
utes following commencement of infusion. After hypoxemiaþ
120 minutes infusion data collection was completed, maternal
hypoxemia was reversed while infusion was continued. Recov-
ery phase data were collected at 30 minutes of maternal nor-
moxemia was achieved. The animals were euthanized at the
end of the experiment with an intravenous overdose (1 mg/kg)
of pentobarbital sodium to the ewe. Fetal weights were deter-
mined postmortem.
Statistics
The data were expressed as mean (SD) unless stated otherwise.
Linear mixed model (LMM) was used for repeatedly measured
data. The phase of the experiment and sildenafil treatment (vs
saline) was included as fixed effects, an interaction term, and
individual fetus as random intercept. If LMM showed a signif-
icant difference between measurement points (P [time] < .05),
then a pairwise comparison between relevant points was
performed. The difference between the 2 groups was expressed
as P (group). The 2 groups may not show similar changes with
time (interaction term). Therefore, this was expressed as P
(group  time). The LMM can be applied even when there are
missing data. Not all fetuses survived the whole experiment,
and there were missing values. Hence, LMM was particularly
suitable for this experiment. Statistical analyses were
Figure 1. Timeline of the experiment.
Table 1. Maternal and Fetal Parameters During the Experiment.















Maternal pO2 (mm Hg) Control 168 (47.3) 48 (9.0) 45 (8.3) 44 (5.5) 133 (36.0) <.005 .178 .141
Sildenafil 164 (75.0) 48 (5.6) 47 (4.4) 44 (5.6) 89 (32)
Maternal pCO2 (mm Hg) Control 37 (5.7) 35 (3.2) 35 (3.1) 35 (4.1) 41 (3.1) <.005 .004 .169
Sildenafil 42 (3.8) 39 (3.9) 38 (4.0) 40 (4.3) 41 (4.8)
FHR (beats/min) Control 173 (32.1) 170 (27.9) 177 (27.5) 171 (19.4) 158 (23.1) .011 .506 .671
Sildenafil 171 (30.8) 174 (24.3) 165 (20.5) 157 (20.1) 146 (20.6)
MAP (mm Hg) Control 49.1 (10.2) 42.7 (10.7) 47.0 (15.3) 46.3 (10.2) 50 (10.8) .001 .201 .042
Sildenafil 45.4 (9.8) 42.9 (10.7) 40.2 (9.0) 35.3 (3.5) 36.4 (4.4)
Fetal CVP (mm Hg) Control 3.5 (5.2) 3.4 (3.7) 3.0 (4.5) 2.2 (5.6) 2.0 (3.4) .774 .96 .144
Sildenafil 2.5 (1.7) 2.7 (2.9) 0.67 (1.9) 3.5 (3.0) 3.4 (2.5)
Fetal arterial pH Control 7.32 (0.05) 7.30 (0.03) 7.21 (0.06) 7.15 (0.12) 7.18 (0.06) <.001 .046 .378
Sildenafil 7.25 (0.04) 7.25 (0.05) 7.19 (0.08) 7.06 (0.16) 7.09 (0.16)
Fetal arterial pO2
(mm Hg)
Control 21 (2.5) 12 (2.9) 12 (2.9) 11 (1.1) 21 (2.9) <.001 .306 .004
Sildenafil 21 (6.2) 13 (1.7) 11 (2.0) 11 (3.5) 15 (5.2)
Fetal arterial pCO2
(mm Hg)
Control 49 (7.6) 50 (3.5) 52 (6.1) 52 (7.3) 51 (3.4) .004 .003 .136
Sildenafil 55 (8.6) 55 (7.9) 58 (7.7) 66 (17.7) 57 (8.4)
Fetal arterial base excess
(mM/L)
Control 1.70 (2.51) 2.36 (2.92) 7.00 (5.10) 10.18 (6.01) 9.00 (3.57) <.001 .584 .729
Sildenafil 3.75 (3.28) 3.17 (2.89) 6.08 (4.60) 11.36 (7.65) 10.56 (7.89)
Fetal arterial lactate
(mM/L)
Control 4.03 (1.77) 4.03 (1.77) 7.69 (3.52) 9.73 (4.01) 9.59 (4.06) <.001 .968 .262
Sildenafil 3.62 (1.88) 3.62 (1.88) 6.43 (1.88) 10.33 (4.02) 10.82 (4.56)
Abbreviations: CVP, central venous pressure; FHR, fetal heart rate; MAP, mean arterial pressure.
Note: Significant results are indicated in bold.
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performed using SPSS (IBM Corp, Released 2011, IBM SPSS
Statistics for Windows, version 20.0; IBM Corp, Armonk, New
York) and SAS (version 9.3; SAS Institute Inc, Cary, North
Carolina). A 2-tailed P value <.05 was considered statistically
significant.
Results
Maternal weight, heart rate, and blood pressure values in the
sildenafil and control groups were comparable during the entire
experiment (P > .05 for all; data not shown). Figure 1 shows the
timeline of the experiment. Maternal pO2 at baseline was sig-
nificantly higher (P < .005) than all other experimental phases
(Table 1). Maternal partial pressure of CO2 (pCO2) at baseline
and recovery were significantly different than all other phases.
Mean (SD) fetal weight was 2.44 (0.28) kg and 2.38 (0.34)
kg in the control and sildenafil groups, respectively. There was
no significant difference between the gestational age of the 2
groups (P ¼ .345).
The fetal heart rate in the recovery þ infusion phase was
significantly lower compared to baseline in both the groups
(P ¼ .002). As expected, fetal pO2, pH, and base excess
decreased progressively during the experiment (Table 1). In
the recoveryþ infusion phase, fetal pO2 remained significantly
lower in the sildenafil group when compared to the control
group (Table 1, Figure 2A). In the sildenafil group, fetal pCO2
in hypoxemia þ 120 minutes infusion phase and recovery þ
infusion phase was significantly higher as compared to the
control group (Table 1, Figure 2B). Fetal lactate progressively
increased with no difference between the groups. In the silde-
nafil group, fetal MAP was significantly lower in hypoxemiaþ
Figure 2. Fetal pO2 (A), pCO2 (B), and mean arterial pressure (C) during the experiment. Solid line represents saline and dashed line as
sildenafil. Phase 1: baseline; phase 2: hypoxemia; phase 3: hypoxemia þ 30 minutes infusion of saline or sildenafil; phase 4: hypoxemia þ 120
minutes infusion of saline or sildenafil; phase 5: normoxemia þ infusion of saline or sildenafil. A, *denotes significantly difference as compared to
baseline and recovery þ infusion phase in both groups. Significant difference between sildenafil and saline group (P < .005) in the recovery þ
infusion phase. B, *denotes significantly higher as compared to baseline (P ¼ .001) and hypoxemia phase (P ¼ .003) only in the sildenafil group.
C, *denotes significantly lower as compared to baseline (P ¼ .012) only in the sildenafil group.




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































30 minutes infusion, hypoxemia þ 120 minutes infusion, and
recovery þ infusion phases than at baseline and hypoxemia
phase (Table 1, Figure 2C). Fetal MAP remained stable in the
saline group. Fetal systemic venous pressure remained stable in
both groups during the entire experiment.
Fetal hypoxemia did not affect RVCO that remained
unchanged in both groups. However, LVCO and combined car-
diac output fell significantly in both groups during hypoxemia
and remained significantly lower in the recovery þ infusion
phase than at baseline (Table 2, Figure 3A). In both groups,
QP decreased and both QDA and RPA PI increased significantly
during hypoxemia with no difference between the sildenafil and
control groups (Table 2, Figure 3B and C). During hypoxemia,
systemic vascular resistance fell significantly in both groups, and
it returned to baseline level in the recovery þ infusion phase
(Table 2, Figure 3D). Again, there was no significant difference
between the sildenafil and control groups.
At baseline, LV global longitudinal strain showed more
deformation (P ¼ .001) than the RV global longitudinal strain
with no difference between the groups (Table 3). During
hypoxemia, LV global longitudinal strain deformation was
reduced (P ¼ .003) in both groups (Figure 4A). On the other
hand, RV global longitudinal strain remained stable in both
groups during hypoxemia. Both RV and LV IVRV (Figure
4B and C) decreased significantly during hypoxemia. On the
other hand, only RV IVCV was affected by hypoxemia (Figure
4D), while LV IVCV remained stable (Table 3). In fetal cardiac
functional parameters, we found no significant differences
between the sildenafil and control groups during the experi-
ment. The DV PIV increased significantly in both groups dur-
ing recovery þ infusion phase compared to baseline (Table 3,
Figure 4E).
Response of the fetal heart rate and MAP to acute hypox-
emia in the study is shown in Figure 5A and B, respectively.
Figure 3. Fetal left ventricular output (A), pulmonary volume blood flow (B), ductus arteriosus volume blood flow (C), and systemic vascular
resistance (D) during the experiment. Solid line represents saline and dashed line as sildenafil. Phase 1: baseline; phase 2: hypoxemia; phase 3:
hypoxemiaþ 30 minutes infusion of saline or sildenafil; phase 4: hypoxemiaþ 120 minutes infusion of saline or sildenafil; phase 5: normoxemiaþ
infusion of saline or sildenafil. A, No group differences (P ¼ .376). *Significantly different than baseline (P < .002) for each phase. B, no group
differences (P ¼ .872). *Baseline significantly different than all other phases (P < .003). C, No group differences (P ¼ .169). *Baseline significantly
different than all other phases (P < .003). D, No group difference (P ¼ .513). Differences marked with *P ¼ .025, **P ¼ .007, and ***P ¼.004
significantly different compared to baseline. No difference in the recovery þ infusion phase (P ¼ .079).
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A reduction of fetal heart rate is seen with acute hypoxemia, but
this lasts over 5 to 10 minutes of acute hypoxemia.
Discussion
Our study, using an instrumented sheep at near-term gestation
model, demonstrates that sildenafil infusion given directly to
the fetal circulation did not reverse hypoxemia-induced vaso-
constriction in the pulmonary arterial bed. Furthermore, silde-
nafil did not ameliorate fetal cardiac systolic or diastolic
dysfunction during hypoxemia.
Fetal hypoxemia altered the fetal central circulation. During
fetal hypoxemia, we found a decrease in lung volume blood
flow and a concomitant increase in the volume blood flow
across the ductus arteriosus. Our results confirm previous
observations.4 Consequent to a drop in lung volume blood
flow, venous return to the left atrium decreases, thus leading
to reduced LV and combined cardiac outputs. Fetal LVCO is a
sum of volume blood flow across the foramen ovale and lung
volume blood flow. We have previously shown that ductus
arteriosus occlusion increases only lung volume blood flow
while the volume blood flow across the foramen ovale remains
unchanged.15 This suggests that foramen ovale volume blood
flow is at its maximum capacity, and fetus is unable to increase
it. Therefore, lung volume blood flow becomes critical in main-
taining adequate LVCO and cerebral blood flow and perfu-
sion.19 In the present study, sildenafil infusion given directly
to the fetal circulation did not reverse increased pulmonary
vascular impedance induced by fetal hypoxemia and did not
increase lung volume blood flow. These findings in the sheep
fetus are potentially even more clinically important for the
human fetus because in the sheep fetus at near-term gestation,
the lungs receive 7% of combined cardiac output,20 which
makes it 20% of the LV output. In the human fetus, the
proportion of LV output contributed by pulmonary venous
return is even greater. Pulmonary venous return constitutes
50% to 60% of LV output in the third trimester of pregnancy.
Sildenafil infusion was given via a central vein (superior vena
cava) and therefore should have reached the lungs without
passing through the metabolically active organs, such as the
placenta or the liver.
Fetal pulmonary circulation is known to be responsive to
sildenafil at this gestation. Significant vasodilatation is pro-
duced by sildenafil infusion in normoxemic and hyperoxic
sheep fetuses.14 It is possible that other vascular regions of the
circulation are more sensitive to sildenafil, and its effect on
pulmonary circulation is masked by vasodilatation in the sys-
temic circulation. Endothelial nitric oxide synthase (eNOS)
requires O2 to produce NO,
21 and thus it is possible that the
pO2 levels in the hypoxemic fetus are low enough to limit
eNOS activity. Therefore, another possible explanation is that
in the presence of hypoxemia, pulmonary vasculature is no
longer responsive to sildenafil treatment. Reduced lung blood
flow may limit the amount of sildenafil reaching the lung cir-
culation, thereby masking sildenafil-induced vasodilatation.
Fetal MAP responded differently to hypoxemia in sildenafil
group and this finding could support our theory. The finding
of a reduction in the MAP in response to hypoxemia and silde-
nafil agrees with a previous report.22 The pO2 levels were
lower, pCO2 higher, and MAP lower in the recovery phase
compared to baseline, only in the sildenafil group. This may
be due to problems with placental gas exchange associated with
sildenafil exposure. We are not aware of any studies reporting
altered gas exchange with sildenafil. The observed differences
could also be secondary to altered distribution of the cardiac
output. We observed that systemic vascular resistance was
reduced following hypoxemia. It has previously been shown
that hypoxemia leads to a redistribution of blood flow and that
Table 3. Fetal Left and Right Ventricular Global Longitudinal Strain, Ductus Venosus PI, IVCV, and IVRV at MV as well as TV Measured During
the Experiment in the Study Group Compared to the Control Group.















DV PI Control 0.83 (0.39) 0.75 (0.33) 0.77 (0.29) 0.80 (0.23) 1.01 (0.41) .001 .353 .295
Sildenafil 0.86 (0.32) 0.65 (0.22) 0.92 (0.51) 0.98 (0.45) 1.18 (0.49)
LV global longitudinal
strain (%)
Control 18.3 (3.04) 16.3 (2.41) 16.4 (3.70) 14.3 (4.13) 14.9 (2.87) .0031 .72 .34
Sildenafil 18.7 (3.82) 14.8 (2.69) 15.3 (3.38) 15.0 (4.27) 17.8 (2.86)
RV global longitudinal
strain (%)
Control 13.8 (4.60) 14.7 (4.86) 12.2 (6.13) 12.3 (6.66) 13.1 (6.58) .39 .44 .93
Sildenafil 14.3 (5.35) 14.8 (2.66) 12.5 (3.50) 13.5 (5.14) 15.3 (2.19)
MV IVCV (cm/s) Control 7.04 (3.67) 6.12 (2.82) 6.12 (2.26) 6.34 (3.51) 7.01 (2.63) .222 .318 .952
Sildenafil 6.76 (3.36) 5.44 (2.91) 4.98 (2.70) 4.81 (2.83) 4.95 (2.07)
TV IVCV (cm/s) Control 5.69 (2.10) 5.11 (1.94) 4.72 (2.05) 4.03 (1.57) 5.11 (1.60) .008 .584 .909
Sildenafil 5.29 (2.42) 4.99 (1.85) 4.79 (2.33) 2.79 (1.38) 4.55 (1.81)
MV IVRV (cm/s) Control 2.76 (1.20) 2.70 (0.95) 2.29 (0.93) 2.90 (1.46) 2.79 (1.31) .001 .168 .144
Sildenafil 2.84 (0.93) 1.97 (1.03) 1.63 (0.85) 1.64 (0.91) 1.85 (0.60)
TV IVRV (cm/s) Control 2.98 (1.18) 2.71 (1.12) 2.42 (0.98) 2.94 (1.45) 2.90 (1.11) .029 .558 .987
Sildenafil 2.78 (1.06) 2.56 (0.78) 2.25 (0.91) 2.56 (0.96) 2.44 (0.99)
Abbreviations: DV PI, ductus venosus pulsatility index; IVCV, isovolumic contraction velocity; IVRV, isovolumic relaxation velocity; LV, left ventricular; RV, right
ventricular; MV, Mitral valve; TV, Tricuspid valve.
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Figure 4. left ventricular (LV) global longitudinal strain (A), tricuspid valve isovolumetric contraction velocity (B), isovolumetric relaxation
velocity (IVRV) of mitral valve (C), tricuspid valve (D), and ductus venosus PIV (E) during the experiment. Solid line represents saline and dashed
line as sildenafil. Phase 1: baseline; phase 2: hypoxemia; phase 3: hypoxemia þ 30 minutes infusion of saline or sildenafil; phase 4: hypoxemia þ
120 minutes infusion of saline or sildenafil; phase 5: normoxemiaþ infusion of saline or sildenafil. A, No group differences (P¼ .723). Differences
marked with *P ¼ .002, **P ¼ .008, and ***P < .001 significantly different compared to baseline. No difference in the recovery þ infusion (P ¼
.055). B, No group differences (P ¼ .584). *Hypoxemia þ 120 minutes infusion significantly different compared to baseline (P < .001). C, No
group differences (P ¼ .168). Differences marked with *P ¼ .017, **P < .001, ***P ¼ .023, and ****P ¼ .045 significantly different compared to
baseline. D, No group differences (P¼ .558). *Significantly different from baseline (P¼ .007) in both groups. In E, no difference with phase in the
saline group. *Significantly different from baseline (P ¼ .008) in the sildenafil group.
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resistance in the carcass and splanchnic circulation increases.4
Giussani et al23 demonstrated that hypoxia was associated with
significant reduction in femoral artery blood flow and increase
in carotid artery blood flow. At a glance, our results may seem
to contradict these reports. However, the placental circulation
receives 40% of the cardiac output in sheep fetuses24 and is a
major contributor to systemic vascular resistance. Our calcula-
tion of systemic vascular resistance included resistance in all
vascular beds, except the pulmonary vascular bed. Therefore, it
is not surprising that the total systemic vascular resistance
(which included placental and cerebral circulations) showed a
small reduction during hypoxemia with a reduction in both
combined cardiac output and MAP. Response of the fetal MAP
to hypoxia is variable, depending on where the blood pressure
was measured. Studies where this measurement is performed in
the cerebral arteries report that carotid vascular resistance did
not change and remained low.23 On the other hand, studies
where the MAP was measured in brachial25 or femoral artery23
report that MAP increased significantly in response to hypoxia.
This discrepancy explains why there was no statistically sig-
nificant change in the total peripheral vascular resistance
despite a reduction in LV and total cardiac output. It has pre-
viously been shown that neuroendocrine system is involved in
fetal defense against hypoxemia.26 However, this should be
involved to a similar extent in either group since the 2 groups
were otherwise comparable. A reduction in fetal heart rate was
seen with hypoxemia, similar to previous observations.23 How-
ever, this response did not last for >10 minutes. Therefore, the
fetal heart rate in the hypoxemia phase was no different to that
seen at baseline.
Fetal hypoxemia led to diastolic dysfunction in both ventri-
cles as indicated by decreased IVRV. In addition, we found
diminished RV IVCV and LV global longitudinal strain, sug-
gesting systolic dysfunction during hypoxemia. These results
confirm previous observations.8,18 In the present study, we
hypothesized that sildenafil would ameliorate the myocardial
dysfunction caused by hypoxemia. Experimental studies in the
chick embryo have shown that in chronic hypoxemic environ-
ment, sildenafil prevents the increase in phosphodiesterase
expression, protects against oxidative stress, and normalizes
nitric oxide bioavailability in the fetal heart.16 All these find-
ings support the hypothesis that sildenafil protects the fetal
heart in hypoxemia. However, in the present study, we found
no significant differences in fetal cardiac functional parameters
between fetuses who received sildenafil or saline during
hypoxemia. Our results suggest that these myocardial protec-
tive measures activated by sildenafil treatment are not reflected
in improved cardiac function in hypoxemic sheep fetuses.
Furthermore, species differences and length of hypoxic expo-
sure may play a role in these findings.
We found an increase in the DV PI during recovery phase in
both groups. Fetal systemic venous pressure did not change
during the entire experiment, thus excluding it as a cause of
increased DV pulsatility. Therefore, the most likely explana-
tion for increased DV pulsatility is that the fetal heart rate was
significantly lower in the recovery phase, as a negative correla-
tion is known to exist between heart rate and PI of vessels.27
Our study has some limitations. The surgical procedures
may constitute a significant stress on the sheep fetuses, and it
may be argued that the conditions are quite different from
human fetuses exposed to hypoxemia. The postoperative
recovery period should be long enough for the recovery of fetal
myocardial function.28
Normal arterial blood gas values at the baseline phase sug-
gest conditions close to physiologic circulatory state. Avail-
ability of invasive data and fetal oxygenation status lend
important validation to the results, which is usually impossible
to obtain in clinical settings. The study was carried out in a
narrow gestational age window of 120 to 134 days and may
limit the validity and significance outside this time period. The
sheep model has been extensively used for research in fetal
cardiac function and hemodynamics. We used sildenafil as an
intravenous infusion to the fetus. Studies on the use of silde-
nafil in placental insufficiency administer the drug to the
mother over a period of days to weeks13,29 as opposed to hours
in the present study. Therefore, extrapolation of these results to
human pregnancy should be done cautiously. The use of
anesthesia may have affected the results of the experiment.
However, indexed cardiac output, baseline arterial pO2, and
Figure 5. Response of fetal heart rate (A) and mean arterial pressure
(B) to hypoxemia. Measurements are taken every 5 minutes. Acute
hypoxia was commenced at t ¼ 0. Error bars denote 1 SEM. SEM
indicates standard error of the mean.
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arterial pO2 following hypoxemia are remarkably similar to
those reported by Cohn et al5 in unanesthetized animals. Iso-
flurane can modify fetal cardiovascular regulation. Invasive
and Doppler echocardiographic volume blood flow calcula-
tions correlate well (Schmidt et al, 1991). Moreover, the
intraobserver variabilities of Doppler ultrasound parameters
in fetal sheep are comparable to those found in human
fetuses.1,30 Invasive measurements could have been obtained
in unanesthetised animals. However, obtaining reliable ultra-
sound measurements without the use of anesthesia is techni-
cally not possible and is in the postoperative period unethical.
Furthermore, newborn lambs under isoflurane anesthesia can
increase cardiovascular performance during stress.31
In summary, fetal hypoxemia led to pulmonary arterial
vasoconstriction, decreased lung volume blood flow, increased
shunting through the ductus arteriosus, and a reduction in
LVCO. Sildenafil, when given directly to a hypoxemic fetus,
could not reverse this redistribution of cardiac output. Further-
more, fetal cardiac systolic and diastolic dysfunction observed
during hypoxemia could not be ameliorated by sildenafil
treatment.
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